

REVISITING ACCEPTED WISDOM IN THE MANAGEMENT OF BREAST CANCER

Harriet Beinfield, LAc, and Malcolm S Beinfield, MD, FACS

Harriet Beinfield has practiced acupuncture and Chinese herbal medicine for 24 years at Chinese Medicine Works in San Francisco, Calif. She is the coauthor, with Efrem Korngold, of *Between Heaven and Earth: A Guide to Chinese Medicine*. **Malcolm S Beinfield** is an associate clinical professor in the Department of Surgery at Yale University School of Medicine and on the staff of the Yale Comprehensive Cancer Center. He has practiced surgery for 45 years and has published numerous articles on clinical breast cancer research.

Misconceptions and illusions prevail in the management of breast cancer. Historical review reminds us that medical practice is commonly rooted in tradition rather than proof. The Halsted mastectomy inadvertently served the burgeoning profession of surgery in the early 20th century more than it has benefited women with breast cancer, yet 100 years later the operation continues to thrive. Despite evidence that mastectomy, radiation following lumpectomy, axillary node dissection, or intensive follow-up surveillance have little impact on survival, these practices are adhered to tenaciously. The extent to which current treatment for breast cancer succeeds in prolonging life remains open to question. Many accepted ideas and interventions are perilously disconnected from their true merit. The imperative for doctors to do something sometimes contradicts their pledge to do no harm. Reflection on what is known should guide future action. (Alternative Therapies in Health and Medicine. 1997;3(5):35-53)

When my father was 14 years old, instead of dangling a fishing pole with his father on Saturday mornings, he dashed downstairs to assist him with tonsillectomies. Light fastened on his forehead like a coal miner, he peered past the tonsillar arch into the long tunnel leading to the enigmatic interior, confirming what he had known since he was 5 years old: he too wanted to be a surgeon. Inquisitive, he questioned his father about the purpose of their mission. This was

Brooklyn in 1935, a time when removing the tonsils was believed to be a prophylactic measure that would deter downstream health crises.

The tonsils were conceptualized to be the repository of streptococcal bacteria, the ubiquitous source of rheumatoid arthritis, nephritis, and rheumatic fever. To be a responsible physician meant helping patients to avoid harm. Consequently, two generations lost their tonsils to good medicine. Because the only indication needed for a tonsillectomy was an occasional sore throat and the presence of tonsils, business boomed for my grandfather in those Depression years. Mrs Derringer, the nurse, made a salary of \$8 per week, while the removal of each pair of tonsils cost \$15. (This globally included the surgical fee, home-office operating room, anesthesia, and 6 hours in recovery.)

More than a dozen of these procedures were performed each day in my grandfather's basement clinic. The standard of care was plain and clear: the surgery relieved patients of otherwise anticipated pain and suffering, kept doctors in their position of useful service, and constituted a procedure that the profession had learned to do well. By the time I was 4 years old in 1950, my grandfather, by then at Long Island College Hospital, removed my tonsils. Today tonsillectomies are no longer believed to confer any protective benefit against degenerative disease. The original theory has been disavowed and the rate at which they are performed has plummeted.

Standards of medical practice are established by well intentioned authorities first and, ideally, validated by science later. At this moment, Sally's head is covered in peach fuzz, though her chemotherapy ended 4 months ago. A 38-year-old mother of three (Billy, her eldest, is not yet 9), Sally joined the 184,000 women last year to be diagnosed with breast cancer, hoping not to become one of the 46,000 to die of the disease this year. She did not hesitate to comply with the advice of her doctor to undergo a mastectomy and the removal of a sampling of the lymph glands under her arm (to track traces of the disease that may have spread beyond the breast). When Sally awoke, still groggy, she asked, "How did it go?" Her physician replied confidently, "Don't worry, we got it all," and Sally, relieved, believed him.

Although there is no ambiguity on Sally's part about wanting to do whatever may be required to stay alive and raise her children, there is a woeful gap between our collective wish for a

Reprint requests: Harriet Beinfield, Chinese Medicine Works, 1201 Noe St, San Francisco, CA 94114, (415) 285-0931.

remedy for breast cancer and medicine's ability to furnish one. There is a further schism between what we know and what we do—a split that could be mended. Incongruities, misconceptions, and illusions surround the prevailing rituals employed in the management of breast cancer. Perhaps doctors, rather than being a syndicate of sinister conspirators, are prey to the simpler motive of wanting to rescue and redeem; and women, in their eagerness to be saved, are willing to surrender and endure, by any means necessary.

Reassurance by Sally's doctor is emblematic. Much of the profession has mistakenly confused its best hopes for women with a prognostic and therapeutic competence that does not exist. Regrettably, *there has been no significant improvement in the survival of women in 100 years*,¹² despite publication of William Stewart Halsted's 1894 paper³ heralding his results on "operations for the cure of cancer of the breast." For an entire century, the principle of the Halsted mastectomy has been the cornerstone for the management of breast malignancy, even though a review of the data reveals that mortality hardly declined between the years of 1925 and 1990.⁴

Science is nothing if not an attempt to let the evidence speak for itself, assume its own authority, contradict hypotheses once taken for granted, and, if necessary, remake the rules. Medicine, guided by science, takes its lead from that which is proven—if not in laboratories, then in clinical study. Its Hippocratic dictum is to do no harm, but what does this mean?

At a symposium on breast cancer in 1984, pathologist Edwin Fisher⁵ remarked, "Conceptual aspects of most diseases in medicine—such as breast cancer—have been notoriously rigid. Historically, practitioners have been resistant to change." Surgeon Anaxagoras Papaioannou^{6,7} comments that "[a] conceptual dichotomy has thus evolved: we accept breast cancer basically as a systemic disease but we persist in treating it primarily as a locoregional problem.... [T]here are some limited, uncontrolled, but intriguing data in women with breast cancer that suggest that the less physicians do, either by surgery, irradiation, or by both, the better the patients do."

After Sally was told she had breast cancer, she was unequivocal about what she wanted from her friends: absolute support for the decisions she was making. I had the impulse to share with her what I knew from 30 years of conversations with my father, whose specialty was breast surgery. But it was too late. She made it clear that to be her friend meant not to question her doctor's opinions. "He's not my congressman," she said, "he's my lifeline." Agitated by fear and muddled by the conflicting opinions of experts, she was focused single-mindedly on heeding her doctor's advice.

Breast cancer is a disease enmeshed in contentious debate. Friction does not revolve solely around techniques, but becomes heated as theoretical models diverge. Inquisitions have been held over contested portraits of reality. As irrefutably as diabetes is a medical rather than surgical problem, breast cancer wobbles across boundaries, straddling internal medicine, surgery, radiology, and oncology. Sally couldn't consider that anything other than surgical intervention would deliver and protect her from

harm. In her haste to just want to make it better, she was incapable of considering her options.

Exposing and exploring the premises that have shaped the menu of current choices is itself worthy. How breast cancer is experienced may change as the perception of it shifts. In the summer of 1989 my father traveled to France to witness the early laparoscopic cholecystectomies—removal of the gall bladder via a surgical instrument inserted into small incisions in the belly rather than the former open-abdomen operation. At present, the newer, less invasive surgery has virtually replaced the former operation, reducing patient recuperation time and expense. Continuing with the old operation (except in special circumstances) is now considered unforgivable—no surgeons could justify the more extensive procedure. Yet lumpectomy for breast cancer has still not "caught on." Marc Lippman, a renowned breast cancer researcher, says, "I am puzzled as to what combination of educational, prejudicial, financial, and historical issues have failed to get lumpectomies going.... Most [women] do not choose mastectomies...." Yet they have them anyway. The problem, he said, "is the doctors" (*New York Times*, May 5, 1993).

Unlike gall bladder surgery, about which there is no controversy, different postulates underlie the rationale for mastectomy and lumpectomy. Until the 1960s, breast cancer was conceived as a methodical march from a central encampment outward, like a company of soldiers filing from a barracks to outlying regions via two terrains: along mountainous muscles and through marshes of lymph. Now, it is indisputably held that cancerous cells travel to distant sites (metastasize) via the bloodstream. It is also indisputable that, in a majority of women, this happens years before a tumor is or can be detected. By the time detection has occurred, either by palpation or mammography, the tumor has been germinating for approximately 10 years.

The Achilles heel is that, whereas cancer originates in the breast, it has the potential to spread. The word "cancer" derives from the Latin meaning "crab-like" because it claws and crawls into other tissue. Women do not perish from the local problem, but from the systemic one—and whether or not they do, and when, is dependent on the biological properties of the tumor: how fast and aggressively it multiplies, scatters, and infiltrates. It is now believed that individual body ecology is also a factor—the relationship between the seeds of the disease and the body-soil in which they are planted. Some think that within this tumor-host relationship, immunity is as significant as the virulence of the malignancy. To know whether the tumor has shed cells that have migrated to other parts of the body is only possible in retrospect—after there is evidence of malignant breast tissue growing in the bone, liver, lungs, or brain. No satisfactory method exists for detecting micrometastases or the trajectory of single cells that travel through the blood and lymph—some finding a home and colonizing. Even less mechanistic theories have been proposed, suggesting that genetic factors (inherited or mutagenic) cause normal cells to transform and become malignant, a process that is wholly out of reach of the surgeon's scalpel.

It is all the more baffling that, fully aware of these data, Sally's doctor assured her by saying, "We got it all." What he meant was, "I hope that you have no cells maturing in a distant site, but there is no way for me to know that. What I know is that the 1.5-cm tumor that was in your breast is no longer there, and that this would be the case whether we'd done a mastectomy or lumpectomy. The reason I did a mastectomy is to prevent local recurrence, even though I'm aware that local recurrence itself has no impact on survival and that women who have lumpectomy live just as long as those who have mastectomy. Survival depends on the systemic picture." If the horse bolted before the stable door was shut, no repair of the barn or its latch will be of consequence. Similarly, no use will come of removing more and more breast, or the chest wall, or nearby lymph tissue, if the malignant cells have taken up residence in the femur, liver, or lungs.

By now it's well known: it is not necessary for a woman to lose her breast in an effort to save her life. Yet the majority of physicians still subscribe to the belief that mastectomy is the "gold standard," even though they are fully cognizant of equivalent outcomes for the less invasive lumpectomy. Despite the National Cancer Institute's (NCI) declaration in 1990 that lumpectomy followed by radiation is the preferred therapy (note 1), only 26% of diagnosed women today receive the breast-conserving lumpectomy. Most doctors advise in favor of mastectomies, and most women have them, demonstrating that data alone are not powerful enough to spur change—in medical or social practice.

In Vienna in 1848, for example, Ignaz Semmelweis discovered that women who died following childbirth of puerperal fever were infected as a result of physicians failing to wash their hands between deliveries. Yet because of the complete entrenchment of practice, doctors not only offered up great resistance to his ideas, but fiercely ridiculed him for suggesting that respectable physicians needed to wash their hands. Even though the death rate in Semmelweis's clinic dropped immediately, it was not until Louis Pasteur presented his theory of germs 3 decades later that routine cleanliness was integrated into practice.

Thirty years after encouraging the continuation of the war in Vietnam, former Secretary of Defense Robert McNamara⁸ said in retrospect that we should have left sooner. What is categorical and undisputed in one epoch may be reversed in another. One hundred years after William Stewart Halsted popularized what came to be known as the Halsted mastectomy, the large majority of women diagnosed with breast cancer still undergo a modified version of his procedure—even though no good data indicate that mastectomies have ever effectively resolved the wracking actuality of cancer.

This rather drastic surgical routine has flourished during the same century that ushered in the domain of science with its stringent standards of efficacy. How did a speculative hypothesis become converted into an unquestionable dogma, slipping through the net of scientific rigor and leading even the most conscientious to forsake corroboration? Somehow the correlative has been twisted and tangled into a confused web of causality, and fingers have been pointed in mistaken directions.

Scientific facts are not merely discovered—they are produced. Laboratories are not sterile environments from which subjectivity is hygienically excised, but a place where physicians immersed in their own value systems rely on conceptual models and draw on their personal experience. Medicine is as much a cultural product as a scientific endeavor. Acceptance of medical ideas hinges not solely upon evaluations of impartial evidence, but also upon social networking, political savvy, patronage, and an adherence to protocols in vogue. Medical knowledge, like any other, is contingent on the context within which it is constructed. Subject to voluminous acts of interpretation, it is a perpetual challenge to keep a keen eye on clinical efficacy.⁹

RECENT HISTORY: LABOR PAINS AND THE BIRTH OF A PROFESSION

Today medical institutions have such massive weight and are so embedded within our social landscape that they appear as creations of nature, like the Rocky Mountains. It was not so long ago, however, that the medicine familiar to us today was born. To fathom how Halsted's promulgation of the mastectomy has advanced virtually uncontested since the close of the 19th century, the ground from which it emerged must be sifted, including medical thinking in Europe toward the close of the 19th century, the cultural climate in America, the social history of American medicine, and the burgeoning professionalization of surgery. The singular influence of William Stewart Halsted himself must also be pondered.

There was tremendous activity in medicine toward the end of the 19th century. The profession of nursing originated in London after the Crimean War, when Florence Nightingale founded a school for nurses in 1860. In America Clara Barton founded the Bellevue Hospital School for Nurses in 1873. By 1900 there were 432 nursing schools, and by 1910 there were 1129 more. The trajectory of surgery as a profession mimicked nursing: whereas Midwesterners William and Charles Mayo recorded only 54 operations in the 3 years before 1893, in 1900 they chronicled 612; by 1904 the number exceeded 1000. Wilhelm Roentgen's discovery of x-ray technology in 1895 improved diagnosis, and by 1916, with the aid of Marie Curie, new treatments were being generated as well. Furthermore, the flowering of surgery can be attributed to the discovery of ether as anesthesia, permitting operations to be performed without undue pain; the disinfectant carbolic acid, averting sepsis; and the honing of specialized skills, distinguishing expert surgical craftsmen from the less competent general practitioners.

In Vermont in 1843 there was a 50-cent fee for a doctor's visit at less than half a mile, a \$1 fee between a half and 2 miles, \$1.50 for 2 to 4 miles, and \$2.50 for more than 4 miles. In a 1910 survey, 96 physicians using horses reported costs that worked out to 13 cents per mile, whereas for 116 doctors using cars for which they paid less than \$1000, the cost per mile was 5.6 cents. The advent of the automobile considerably widened the market.¹⁰

Although ether anesthesia was first demonstrated at the Massachusetts General Hospital in 1846, postsurgical infections

caused such high mortality that major surgery was nicknamed a “capital operation.” Neither carbolic acid, needed to eliminate microorganisms during surgery, nor sterile procedures were accepted practice until much later. Joseph Lister published papers on antiseptics in 1867 and lectured for 3 hours on the subject at a medical congress in Philadelphia in 1876.¹¹ But at the first meeting of the American Surgical Association in 1883, more speakers opposed his principles than supported them, steadfastly disregarding reports that in European hospitals that implemented his methods, postsurgical problems such as gangrene were no longer rampant. As late as 1900 most surgeries were conducted in the home because hospitals were feared as filthy, foul houses of death.

In 1847, the American Medical Association (AMA) was founded in an effort to upgrade the profession. They vowed that raising educational standards was their ticket, but it took another 60 years for their train to pull into the station. The AMA tracked the career choices of 12,400 men graduating from elite colleges between 1800 and 1850, finding that only 8% became physicians, while more than three times that many entered the clergy and legal professions. The AMA interpreted this as signifying a disdain for medicine among “educated talent.”¹⁰ Confirming their suspicions, in 1880 fewer students at medical schools had bachelor’s degrees than at either law or divinity schools.

In those days, medicine offered more status than wealth—doctors were a cut above manual laborers. Unable to earn a living solely by practicing medicine, doctors cultivated livestock, pulled teeth, mixed herbal preparations, nursed patients through long and difficult nights, and embalmed the dead. Throughout medical history surgeons were regarded as the least sophisticated and learned craftsmen in the guild, trained principally in the use of their hands through apprenticeship, many with barber-surgeons. A carryover of this remains in England today—internists are referred to as doctor, and surgeons as mister, denoting their lesser rank.

As for the specialty of surgery, in 1876 Samuel Gross of Philadelphia wrote his observations about the American surgical scene: “Although this paper is designed to record the achievements of American surgeons, there are, strange to say, as a separate and distinct class, no such persons among us. It is safe to affirm that there is not a medical man on this continent who devotes himself exclusively to the practice of surgery.”¹² It was Gross who founded the American Surgical Association in 1880, but it would take at least another 2 decades for surgery to become established as a legitimate profession.

Although doctors were aspiring to an image of erudition, few actually completed much higher education. Both of my grandfathers graduated from Long Island College Hospital in 1914 with high school diplomas, never having attended college. Henry Beinfeld went on to perform tonsillectomies, earning \$900 a week while his nurse and chauffeur earned \$8, whereas Harry Koster set up his own research hospital, frequently publishing in *JAMA* and *Archives of Surgery*.

Princeton sociologist Paul Starr^{10(pp79,80)} says, “Acknowledged

skills and cultural authority are to the professional classes what land and capital are to the propertied. They are the means of securing income and power. For any group, the accumulation of authority requires the resolution of at least two distinct problems. One is the internal problem of consensus; the other is the external problem of legitimacy.”

In terms of consensus, physicians were struggling mightily to come to agreement about their common rules and standards. Internal divisions beset the profession from the mid-19th century until the early part of the 20th century. Concerning legitimacy, in Europe medical degrees granted deference and respect, but in America the meager educational requirements left physicians with a perilously slender margin between themselves and their patients—and sometimes no margin at all. Therefore their powers of persuasion, along with their ability to kindle feelings of confidence and trust, were critical to their success. In America a physician’s standing was tied to his own family background, as well as the social rank of his patients. At the top were men who, like William Stewart Halsted, had graduated from elite colleges, attended medical school, and received further instruction in Europe.

Although the AMA was in its infancy in the mid-19th century, it wasn’t until 50 years later—the early 1900s—that medical societies began replacing the internal dissension and competitive relationships among doctors with a brotherhood of shared interests (note 2). But in 1900 the AMA still sought to address the issue that had motivated its formation: control of medical education. This was the chosen methodology to consolidate the profession: standardized schooling would ensure both conforming ideas and uniform practice.

Reform of medical education had its beginnings in the 1870s when the Quaker merchant Johns Hopkins died in 1874, willing half of his \$7 million estate to found a university, and the other half to build a hospital. At the time, this was the most substantial endowment in American history, setting the precedent for linking laboratory research with clinical patient care. The prototype came from Europe, where laboratories in physiology, chemistry, pathology, and histology were transforming hospitals. Johns Hopkins University opened in 1876, the hospital in 1889, and the medical school in 1893. Johns Hopkins School of Medicine had the hitherto unheard of admission requirement of a bachelor of arts degree, and the curriculum was lengthened from 3 to 4 years. The crucial half million dollars needed to complete the school was donated by wealthy Baltimore women who made their offer contingent upon the admission of women on the same basis as men.

Johns Hopkins was the paragon of virtue in the eyes of the AMA. This single institution had—and continues to have—enormous leverage on the course of medicine. The policies ensconced there determined which institutions survived to govern the field, how they were structured and administered, and what ideology would triumph (note 3).

Finally standards were being set for medical education as graduate study, with strength in both science and clinical medicine. The next advance was creating residencies in specialized

fields. Two towering giants in medicine, William Welch, a pathologist, and William Osler, an internist, were dedicated to building Johns Hopkins as the archetype for training not only physicians, but medical scientists as well. Welch, however, vied for the interests of research, whereas Osler championed the interests of clinical medicine. Osler admonished: "Care more for the individual patient than for the special features of the disease.... Put yourself in his place ... enter into his feelings, scan gently his faults. The kindly word, the cheerful greeting, the sympathetic look—these the patient understands."¹³ Osler further expressed concern that patient care might suffer if it became completely subservient to research, but Welch differed, determined to elevate the role of science in medicine.

THEN AND NOW: HISTORY OF CANCER OF THE BREAST

The earliest known chronicle of breast tumors was recorded on Egyptian papyrus more than 3000 years ago, but no treatment was described. During the Middle Ages, mastectomy was wielded as tortuous punishment against women accused of religious or political deviation, such as Saint Agatha, patron saint of the breast. In France in the 1820s it was hypothesized that certain personality dispositions were considered to be more prone to breast cancer than were others. Women with a "bilious constitution and a dejected, melancholy character," for example, were especially predisposed.¹⁴ In Italy in 1842 Domenico Rigoni-Stern analyzed statistical data from death registries and noted that breast cancer incidence increases with age, and that unmarried women are at greater risk than married women.¹⁴ Judgments that blamed sad or angry women for bringing breast cancer on themselves as well as the prescient insight that child-bearing affects the incidence of this disease both occurred more than a century ago, repeating echoes across a historical canyon.

One of the earliest recorded nonpunitive mastectomies was performed by the accomplished surgeon James Syme (whose daughter married Joseph Lister) in a surgical amphitheater in Edinburgh in 1830. Dr John Brown, recollecting the event in 1863, tells us,

Allie stepped up on a seat, and laid herself on the table ... arranged herself, gave a rapid look at James [her husband], shut her eyes ... and took my hand. The operation was at once begun; it was necessarily slow; and chloroform—one of God's best gifts to his suffering children—was then unknown. The surgeon did his work. The pale face showed its pain, but was still and silent.... It is over: she is dressed, steps gently and decently down from the table, looks for James, then, turning to the surgeon and the students, she curtsies—and in a low, clear voice, begs their pardon as if she has behaved ill. The students—all of us—wept like children; the surgeon wrapped her up carefully, and resting on James and me, Allie went to her room.⁴

Four days later, Allie Noble developed an infection that she

did not survive. Surgery was excruciating and death from it a likely possibility before anesthesia and asepsis. Interestingly, Symes also noted in 1842: "The result of operations for carcinoma when the glands are affected is almost always unsatisfactory, however perfectly they may seem to have [been] taken away. The reason for this is probably that the glands do not participate in the disease unless the system is strongly disposed to it."^{4(p650)} British breast physician Michael Baum^{4(p650)} comments that "[t]his statement is of great historical significance for two reasons. Firstly, it illustrates that surgeons long before the Halsted era were attempting perfect clearance of the axilla. In addition, it also illustrates that they recognized that such efforts were futile in the presence of extensive involvement, a sentiment that was ignored for a further 120 years."

Accidents in which women's breasts were caught in the wringers of old-fashioned washing machines were commonplace. After such a mishap, women would visit their doctors because of tenderness, swelling, and pain. Probably because an existing lump was noticed following such an accident, it was supposed that breast cancer was caused by trauma. This is one early example of the coincidental being mistaken for the causative. But for the most part, before routine palpation or mammography, breast cancer was not recognized by subtle signs. Instead, women suffered from glaring complaints, such as oozing ulcerations and the malodorous weeping of distended, deformed, throbbing, eroded flesh. Such agonizing symptoms, even more than implacable death, caused the worst despair. In the context of the times, it was highly desirable to seek a cure for these symptoms—to remove the field upon which the game was played, annihilate the messenger (if not the message), and abort the short-term pain (if not the final demise). Today, though there is a pervasive amorphous panic, a spiny dread of death, in this country there are never open, rank, leaking wounds.

In the 19th century, women with breast cancer were in a social sense considered to be lepers—it was a disgrace as well as a medical problem. As late as the 1960s breast cancer was not publicly discussed and women did not openly volunteer that they had the disease. (It was not until 1974 that by announcing her breast cancer diagnosis, First Lady Betty Ford pierced the public veil on the subject. President Ford did not hesitate to decide that she would have a mastectomy.)

Perhaps what Halsted meant when he promised to "cure" carcinoma of the breast was to remove the immediate and recurring misery, not the disease itself or its eventual outcome. In Halsted's paper, published in 1894, he acknowledges: "The efficiency of an operation is measured truer in terms of local recurrence than of ultimate cure."^{3(p302)} But Halsted's zealous victory over local recurrence assumed a life of its own and later followers confused elimination of symptoms with a remedy for the disease. In the urgency to effect an absolute cure, progressively more and more tissue was expunged in an attempt to avert "recurrence." The concept that removing the breast would erase the disease was irresistibly seductive. It is useful to trace the intellectual origins of this theory.

A Short History of Ideas: Virchow's Influence

Tuberculosis, the sovereign disease of the 19th century, was the leading cause of death, as feared as it was widespread. In Europe, the work of the German physician Rudolph Virchow (1821–1902), the father of “cellular pathology,” advanced medical knowledge. His contributions were substantial; for example, he identified leukemia in 1845 and in 1846 articulated the process by which blood clots become obstructive. At a time when medical focus was narrowed to the courses of particular diseases, Virchow both broadened and magnified the lens by gazing into the nature of specific pathophysiological processes. He mapped the tissue reactions of atrophy, hypertrophy, inflammation, embolism, necrosis, tuberculosis, cancer, fibrosis, and calcification. Many of Virchow's concepts have withstood the test of decades, but a few of his ideas were off course. Because of his immense stature, however, his faulty conclusions were also fully embraced and perhaps disproportionately influential.

Virchow proclaimed the tissue changes characteristic of tuberculosis as emblematic for the disease process in general, and cancer in particular. His revolutionary biological model of breast cancer professed that tumors arose within the skin, rather than as a systemic disorder, invading locally and centrifugally in all directions, spreading along the planes of muscles and through lymphatic channels. Furthermore, Virchow thought that the lymph nodes under the arms acted like filters, blocking the spread of the disease to the organs and skeleton. If the tumor burden penetrated the lymphatic defenses, then the disease progressed in an orderly manner from the center outward to the chest, trunk, upper arms, and thighs.

Virchow was not a clinician. He did not engage in the care of patients, instead focusing solely on tissue reactions in the lab. His positive disdain for clinical evidence became an intellectual trend. A tacit reverence for and acceptance of Virchow's theory that the lymph is the highway of the cancerous process persist today, though we know that metastases require blood supply (angiogenesis) and also travel through the circulatory system to distant (metastatic) sites.

The Legacy of William Stewart Halsted

Virchow and Halsted were characterized by monumental achievements. Just as Virchow was credited as the most influential early figure in German medicine, so Halsted occupies that position in American surgery. More than any other physician, Halsted was personally instrumental in the genesis and rise of the specialty of surgery. First, he performed operations that only highly trained specialists could duplicate; second, he transformed surgical education by establishing a residency program in surgery, overturning a hierarchy in medicine that had endured for centuries in both Europe and America. Halsted singularly hoisted surgeons to the pinnacle of the social caste of medicine.

In 1852, when Halsted was born, his family owned the textile import firm of Halsted, Haines and Company (note 4). Halsted attended boarding school at age 10, graduated from Phillips Andover, and joined the Yale Class of 1874. He then

entered the College of Physicians and Surgeons in New York (which was to become the Columbia School of Medicine) for the customary 3 years, interned at Bellevue in 1876 during medical school, then in 1878 studied for 2 years in the illustrious medical centers of Vienna and Germany. After returning from abroad, Halsted put Virchow's theories into practice, performing operations that removed the entire lymphatic and muscular field surrounding carcinoma. The golden rule for the management of breast cancer hence became the Halsted radical mastectomy.

Halsted introduced techniques and set standards that are now customary, but which at that time were startling surgical innovations—namely, radical *en bloc* removal of the breast; hernia repair; refined thyroidectomy and intestinal anastomosis operations; a completely bloodless operating field and uncompromising sterility; careful, meticulous, anatomically precise surgical dissection that minimized undue trauma to surrounding tissue; direct blood transfusion; and fastidious closure of the wound, layer by layer, with silk sutures.^{11(pp386-421)} When Halsted's operating room nurse and soon-to-be wife, Caroline Hampton, developed a rash from handling irritating solutions of mercuric chloride, Halsted wrote to Goodyear Rubber and requested that they produce an experimental pair of thin rubber gloves. On trial, they were so successful that more were ordered, and now no surgery can be imagined without them. (Although Halsted was neither the first surgeon to perform a mastectomy nor the first to use rubber gloves, because he popularized them in America it is he who is given credit for them [note 5].)

Halsted was surgeon-in-chief and professor of surgery at Johns Hopkins at the time the medical school opened in 1893. Having personally observed the European medical nobility (Virchow, Billroth, Kocher, von Volkmann), he emulated them, hitching the pathology laboratory to the surgical theater, splicing science with clinical practice. Reproducing the best of what he had witnessed a dozen years before, Halsted created the first and foremost surgical residency program in America, directing it for 3 decades. The seeds of his philosophy were sown deep, far, and wide—his residents initiated top-notch residency programs across the country, graduating 166 chief residents who bred successive generations of surgeons. Halsted also trained more than 50 teachers—among them men who became professors of surgery at Harvard, Stanford, Yale, Johns Hopkins, Cornell, Pittsburgh, Cincinnati, Virginia, and other exceptional schools of medicine. This group produced a second generation of 139 teachers of various ranks, influencing a prestigious and vast swath across the geographical landscape of medical education.¹⁵ They proceeded to teach others, insuring that Halsted's views were so broadly disseminated that they became the official guideposts and doctrine of the surgical world.

The early 1880s, a decade before Johns Hopkins Medical School commenced, were productive and prolific for Halsted. He published 20 scientific papers, lectured in anatomy at his alma mater, became an associate in a surgical practice at Roosevelt Hospital, and set up the outpatient clinic there. But by 1885 this had changed and Halsted's ability to deliver lectures as well as

his attendance at professional meetings dramatically waned. Although a well-kept secret at the time (which wasn't confirmed conclusively until 1969, when the diary of William Osler was unlocked and disclosed), Halsted's study in Europe had launched him into a cocaine and morphine addiction that was to last the rest of his life. Halsted's dependence began in Vienna in 1884 when ophthalmology resident Karl Koller discovered that a few drops of cocaine numbed the surface of the eye. This discovery led to the use of local anesthesia and, curiously enough in the light of history, was proposed by none other than Koller's friend, Sigmund Freud, then a 28-year-old neurologist (note 6).

Both Freud and Halsted, inspired by Koller, undertook their own investigations. In 1884, Halsted began injecting this remarkable substance into himself and his colleagues to determine its effect in blocking nerve conduction (note 7). From this time forward, Halsted struggled with a successfully clandestine yet sometimes debilitating addiction that profoundly altered his personality, yet never eclipsed his medical life. Welch, the renown Johns Hopkins pathologist and Halsted's dutiful friend, took him sailing on a 2-month voyage through the Caribbean in the winter of 1886, hoping to correct his habit. But Halsted was admitted to Butler Hospital in Providence for 7 months later that same year, and for 9 months in 1889. Halsted's addiction effectively terminated his career in New York. Again Welch rescued him by inviting him to Baltimore and securing him an appointment at Johns Hopkins.

William Osler, Welch's partner in shaping the medical school as well as its first professor of medicine, regarded as the most eminent clinician of his time, entered in his diary that 6 months after Halsted had been awarded his full position at Johns Hopkins, he saw him in a severe chill, realizing that he was still taking morphia. Having gained one another's confidence, they discussed that Halsted had never been able to reduce the amount to less than three grains daily (one grain equals about 60 mg). Osler also recorded that he did not think anyone suspected Halsted's habit—not even Welch, who assumed the addiction had been conquered. Later Osler added that in 1898 Halsted reduced his dose to 1½ grains—nine times the standard 10 mg of morphine prescribed for severe pain today. Halsted permitted the popular deception to persist that he had been “cured” after his second hospitalization; in the public eye, he was clean. His close friends, however, noted that the socially exuberant extrovert who had studied in Europe had returned strangely altered.

Halsted's distinguished resident, Harvey Cushing—the progenitor of neurosurgery, the chief of surgery at Harvard, and the man for whom Cushing's Disease was named—knew Halsted only after his temperamental shift. Upon Halsted's death in 1922, Cushing eulogized his mentor (*Yale Alumni Weekly*, February 23, 1923), regarded by many as the most eminent surgeon of his time:

[Halsted] was a man of unique personality, shy, something of a recluse, fastidious in his tastes and in his friendships, ... the victim of indifferent health, he nevertheless ...

may be considered to have established a school of surgery comparable, in a sense, to the school of Billroth in Vienna.... [A]n aristocrat in his breeding, scholarly in his habits ... having little interest in private practice, he spent his medical life avoiding patients.... A bed-to-bed ward visit was almost an impossibility for him. If he was interested he would spend an interminable time over a single patient, ... carrying the problem to the laboratory and perhaps working on it for weeks.

Halsted's lack of interest in his patients as people was reminiscent of the heroic Virchow. He was scrupulous and painstaking in the surgery itself, yet harbored an aversion for interaction as a form of caring for his patients. At the same time, he fashioned himself as their savior. Most significantly, the complicated radical mastectomy launched surgeons on a trajectory of prestigious professional accomplishment. Because of the anatomical and technical prowess required, in 1898 surgeon Frederick Gerrish¹⁶ said of Halsted's radical mastectomy: “We now have an operation which should be regarded as unjustifiable for the general practitioner.”

Virchow and Halsted were uncommonly devoted medical scholars and sleuths. Hooked on deciphering pathological mysteries, the interest of science was their priority. Surgery afforded the chance for live dissection, an occasion immensely more instructive than the scrutiny of cadavers. Throughout surgical history, peeking within the pulsing inner sanctum yielded scholarly returns, even when there appeared to be no profit for the patient.

Advances in knowledge sometimes occur in the absence of therapeutic gain—the interests of clinicians and researchers are interdependent, but not necessarily identical. Lithographs of Halsted's early mastectomies illustrate exceptional textbook learning opportunities, showing the skin vividly peeled back from the chest wall, exposing the vast web of glands and vessels. On the other hand, women were left with a large, open chest wound thick with clots that sometimes took months to heal. Halsted defined success by the tissue samples gleaned and the perfection of the technique employed. Ultimately, however, contrary to concurrent insights, he believed in Virchow's notion that cancer spread to muscles via lymph.

As late as 1907, in a follow-up paper titled “The Results of Radical Operations for the Cure of Cancer of the Breast,” Halsted¹⁷ echoed Virchow's flawed theory, writing:

I recall ... cases ... in which general metastasis was believed, erroneously, I think, to have occurred by way of the bloodvessels [*sic*].... We believe, with Handley, that cancer of the breast, in spreading centrifugally ... before involving the viscera may become widely diffused along surface planes.... It permeates to the bone rather than metastasizes to it, and, by way of the lymphatics, along facial planes ... the liver may be invaded by way of the deep fascia ... the brain by the lymphatics accompanying the middle meningeal artery.... Though the area of disease extends

from cranium to knee, breast cancer in the broad sense is a local affection ... invariably by process of lymphatic permeation, and not embolic by way of the blood. If extension, the most rapid, takes place beneath the skin along the fascial planes, we must remove not only a very large amount of skin and a much larger area of subcutaneous fat and fascia, but also strip the sheaths from the upper part of the rectus, the serratus magnus, the subscapularis, and, at times, from parts of the latissimus dorsi and the teres major. Both pectoral muscles are, of course, removed. A part of the chest wall should, I believe, be excised in certain cases, the surgeon bearing in mind always that he is dealing with lymphatic, and not blood, metastases.... It must be our endeavor to trace more definitely the routes travelled in the metastases to bone, particularly to the humerus, for it is even possible in case of involvement of this bone that amputation of the shoulder-joint, plus a proper removal of the soft parts, might eradicate this disease.... So, too ... amputation at the hip-joint may seem indicated.

Halsted proposed the notion that more is better, suggesting the removal of the sheath covering all muscles surrounding the breast, the upper part of the abdominal muscle that extends from the rib cage to the pubis, those that control the motion of the shoulder blade and rotate the arm, and, in some cases, removal of the arm and hip as well. Halsted's hypothesis is captured above: to contain the disease it may be necessary to excise all contiguous areas. Of particular note is that this flawed logic persists today. Cancer continues to be treated more like dry rot in the rafters of a house than microbes in a river.

In 1886 Rudolph Matas (1860–1957), founder of the Tulane School of Medicine and the father of vascular surgery, visited Paris and observed breast operations there. Later, in 1898, Matas¹⁸ followed Halsted's protocol, but remarked,

But if we were to follow this principle of prophylactic extirpation to its legitimate and logical conclusions we would be compelled to control part of the vascular (venous) channels which drain the region, as these are just as likely to serve as avenues of dissemination as the lymph tracts. The impracticability of such a proposition is so grossly apparent that it would be absurd even to refer to it were it not that it demonstrates how imperfect and limited are our surgical resources to cope with this illusive [*sic*] and far-reaching evil. The new operation will unquestionably greatly diminish the probability of *local recurrence*, but the patients will die, as a rule, just as quickly by regional and internal metastases as if a superficial operation had been performed.

It was common sense to Matas that cancer was as likely to spread via the blood vessels as via the lymphatic channels, and that if it had disseminated, no amount of local management would be sufficient. He comments that within the abiding logic, all the blood vessels must be removed, along with the lymphatic

channels—a patently infeasible process. Although the observations expressed by Matas cast Halsted's model into doubt, the two were close personal friends. Because Halsted was his senior, Matas never crossed him.

MEDICAL VERACITY: AUTHORITY VS STANDARDS OF PROOF

Early in the 1900s it was popular to employ gold salts in the treatment of tuberculosis and arthritis. Not until 1924 was a critical experiment undertaken in which, out of 24 people with similar disease, 12 received gold salts and 12 received distilled water. Those receiving the gold fared worse than did the untreated (control) group. Commenting on the experiment in retrospect, Harry Dowling said it was noteworthy because it introduced the notion of controlled therapeutic trials to eliminate false claims of efficacy. In addition, Dowling¹⁹ contended the following: "The lesson was long overdue. If every therapeutic agent advocated for an infectious disease since 1900 could have been studied as rigorously, the medical profession would have fewer remedies, but the patients would have been exposed to less discomfort and danger, the community would have had less expense, and fewer patients would have died."

An experiment similar to the test for the efficacy of gold salts has yet to be undertaken for women being treated for breast cancer. Physicians sometimes issue proclamations that appear more like sacred doctrine than secular investigations. Reflecting on the shift of belief from religion to science in the 19th century, philosopher Søren Kierkegaard noted that visits with priests were being replaced by appointments with doctors. It was they who were deciding who was crazy or sane, sick or well, who should serve in the army and who should not. By determining how people are born and die; by naming disease; by interpreting feelings, behaviors, signs, and symptoms; and by issuing prognoses, doctors assume immense authority.

Authority by nature commands obedience. Medicine acquires cultural authority by dictating definitions of reality and forwarding judgments about which schema of meaning will triumph as valid. It is ironic that in an attempt to implement scientific advances, verification is sometimes ignored and the principles of science are set aside. At times the mere newness of a technology is taken as evidence of its superiority. An intrinsic contradiction in medicine also exists: because solutions are often fragmentary and incomplete—sometimes merely analytical and speculative—doctors try to avoid saying "we know," yet they must act as though they do! There is a grand expectation on the part of patients for deliberate, confident action to relieve suffering.

It is superbly American to, as the Nike advertisements exhort, "Just Do It." The preference for intervention over reflection is codified by tradition and practice; doctors charge higher fees for performing procedures than for cognitive services. Within this environment, in which deeds are valued more than deliberation, certainty more esteemed than doubt, an inexorable faith in future progress also exists.²⁰ It is paradoxical that a blind faith in reason sometimes supersedes the doctrine of proof.

Medical sociologist Paul Starr^{10(p55)} comments that, in the beginning of the 19th century, “[t]he early empirical investigations showed that accepted techniques [like bloodletting] had no therapeutic value, yet there were no effective alternatives available to replace them.” This bears surprising resemblance to the use of mastectomy—there is little evidence to validate its use when compared with lumpectomy, yet in a vacuum of viable alternatives it persists, because *at least it is something that we can do*. Surgeons are loyal to the Nike mentality, even if they wear Gucci on their feet. They are an athletic, action-oriented guild. When Halsted championed mastectomy as “the operation for the cure of cancer of the breast,” he did not attempt anything less than complete conquest—a total solution. As captain of both the Yale boxing and football teams, he was nothing if not a man of action, preferring definitive solutions over thorny dilemmas.

A CHRONICLE OF BREAST CONSERVATION VS REMOVAL

The breast-conserving approach to the management of breast cancer is understood as the excision of the tumor itself, the lump, and a small margin of surrounding tissue, but not the entire breast. This is now called lumpectomy. The challenge to Halsted’s teachings met with a legacy of disregard and disrespect within devout surgical gatherings.

Just as Semmelweis had been ridiculed for suggesting hygiene in childbirth decades earlier, so Sir Geoffrey Keynes of Britain was scorned when he introduced the breast-conserving tumorectomy with a radium needle insertion in the 1930s. Five-year survival rates were similar to those of Halsted’s mastectomy, but Keynes was greeted with profound contempt during his lecture tour in the United States. Twenty years later, failing to adhere to surgical dogma, he was again punished when Scotsman Robert McWhirter spoke at a meeting of the American College of Surgeons. McWhirter suggested replacing radical mastectomy (removal of the breast, pectoral muscles, and lymph nodes) with what is now called a simple or total mastectomy (removal of the breast, leaving muscles and nodes) accompanied by radiation, and thousands of physicians thunderously booed him off the stage. McWhirter was not even challenging the conceptual model—merely simplifying the surgical procedure. Today the modified radical mastectomy (introduced by Patey and Dyson in England in the 1940s) consists of removal of the breast and nodes, leaving the pectoral muscles intact.

In the late 1940s, after attending Yale (Halsted’s alma mater) as an undergraduate and completing medical school, my father, Malcolm Beinfeld, did a surgical residency at Harlem Hospital. Harlem housed several prodigious masters of surgery at the time. However, unlike their counterparts at the Mayo Clinic, Memorial Sloan-Kettering, or Presbyterian hospitals—all of whom were part of the grand establishment of medicine, replete with highly endowed funding for the best and most advanced research—Harlem depended on old-fashioned empirical observation and pragmatic experience. The surgeons at Harlem questioned the logic of mastectomy for their patients with breast cancer. It was not until 1948 that Harlem’s Louis

Wright became the first black surgeon admitted to the American College of Surgeons. Perhaps the forming of independent clinical judgments was facilitated by his status as an outsider.

Joining the clinical faculty at Yale in the 1950s, my father witnessed Drs Ira Goldenberg and Leonard Prosnitz in the 1960s perform lumpectomies followed by radiation therapy. In 1964 he heard George Crile describe animal experiments that refuted the teachings of Virchow and Halsted: cancer cells did not spread predictably, lymph nodes did not act as filters, and access to vital organs occurred via the bloodstream as well as the lymph. In a 1955 article called “Common Sense in Cancer,” Crile²¹ warned against super-radical attempts to accomplish the impossible. He noted that for many surgeons, the presence of cancer justified anything that they elected to do: “They do not admit that attempts to cure incurable cancers usually do harm. Fear of cancer should not be exploited. Surgeons should not subject patients to useless operations in cancer’s name.... This is not the solution of a problem, it is the definition of one.... When we cannot cure, we must be careful that at least we do no harm.”

Yet at the same time that Crile was rethinking the model and suggesting a less drastic surgical intervention, Owen Wangensteen, himself a surgeon of great distinction at the University of Minnesota, submitted that the reason the Halsted mastectomy did not produce better results was that it was *not radical enough*. Wangensteen proposed what he called a super-radical mastectomy, removing not only the pectoral muscles and lymph nodes of the breast and underarm, but the nodes adjacent to the sternum as well as a portion of the first rib and collar bone. It was necessary for him to saw through and split the sternum to excise the lymph nodes in the space around the heart. This brutal surgery required at least several weeks of hospitalization, and a number of women did not survive. To Wangensteen’s credit, he noted his rather poor results, reported the operative deaths, and terminated the use of this procedure. He erroneously thought, however, that his “failure may have been in the execution of the concept rather than in the concept itself.”²²

In the early 1950s, Wangensteen’s contemporary, Jerome Urban at Memorial Sloan-Kettering, excised a sizable portion of the chest wall in order to reach the internal mammary lymph nodes. Bypassing mortality, Urban performed a comprehensive calisthenic surgery (removing more tissue than anybody else) without any proven gain. Wangensteen and Urban were both clinical investigators whose approach to medicine appeared to regard patients primarily as experimental subjects.

In contrast to the super-radical mastectomy, Crile’s arguments began to be echoed by brothers Bernard and Edwin Fisher, who in 1958 began studies that were to culminate in the genesis of the school of “biological determinism”—meaning that the outcome of treatment was predetermined by the biology of a systemic disease process. Unlike many of his predecessors, Bernard Fisher was a pioneer in the application of clinical research methodology, establishing the importance of prospective randomized studies, which have now become the standard. Prospective means preplanned and randomized means selected

by chance (such as every other chart). Through 23 clinical trials with thousands of women over decades, Fisher²³ clearly established that mastectomy had no survival advantage over lumpectomy with radiation in women with a tumor size that conformed to the criteria of the study: 4 cm or less.

It was my father's medical school roommate, Nathaniel Berlin, clinical director of the National Cancer Institute (NCI) through the 1960s and chairman of the NCI Breast Cancer Task Force until 1975, who secured funding for Fisher's studies after Congress passed the National Cancer Act of 1971. The climate was such that Fisher was unable to recruit enough American surgeons into the study—they were unwilling to venture beyond the conformity of ideas and established standards of practice, though Canadian physicians were willing. The atmosphere surrounding the clinical selection of lumpectomy over mastectomy remained charged well into the '80s.

My father performed his first lumpectomy in 1978, but not without derision from his colleagues. On occasion, the women he treated would request a second opinion from another surgeon. If a woman had metastatic disease—sometimes years following a lumpectomy—one colleague of my father's insinuated that had the woman come to him (rather than my father), he would have done the proper operation (mastectomy) and cured her, thus proving he was able to "get it all."

By modern standards, Halsted's studies were sloppy and unkempt. This is not completely incomprehensible, though, because his landmark paper proclaiming "operations for the cure of cancer of the breast" was based on research between 1889 and 1894, the same period that his addiction plagued him so heavily. For the bulk of 1889 he was even hospitalized in Providence. Although Halsted's study covered the period between June 1889 and January 1894, he mistakenly included women in his report from March 1894, three months after the study was closed. Halsted³ stated: "Local recurrence is a return of the disease in the field of operation in the apparent or buried scar." Yet under the heading of women without local recurrence, he included those who recurred on their scar, contradicting himself. He focused on local recurrence, not survival, and tracked the women he saw for 3 years or less. Out of 50 cases, only 3 women were followed and found to be alive 3 years later. Eighteen were followed for less than 2 years, and 43 were followed for less than 3 years. If lumpectomy studies showed anything less than a 5-year survival, they would have been regarded as statistically laughable. But due to Halsted's authority and the ideological loyalty he inspired, his research methodology and results, though poor, never seemed to deter multitudes of followers.

One hundred years later, a double standard still remains. Lumpectomies are held to rigorous standards of efficacy, whereas mastectomies have never been subjected to anything close to the same requirements. A recent scandal has also clouded clear thinking. In 1994 Bernard Fisher, professor of surgery at the University of Pittsburgh, was ousted from his chair of the National Surgical Adjuvant Breast and Bowel Project (NSABP) because an investigator from Montreal, Roger Poisson, commit-

ted acts of scientific misconduct on Fisher's watch. Poisson altered surgical biopsy dates for 6 patients so they would be eligible within the Protocol B-06 requirements. His actions, irresponsible because of the deceit involved, did not, however, affect the end results. All 354 patients at his hospital were eliminated from the total group of 2163 women by subsequent auditors, and adequate numbers remained to assure overall credibility for the study, which covered the period between 1976 and 1984.^{24,25}

There were, however, public alarm and breach of trust over this incident. Even though no patient's welfare was compromised, and no research outcomes were altered, the safety of lumpectomies was thrown into question by newspaper headlines that did not fully explain the nature of the error, possibly setting back use of this breast-conserving procedure. Now extensive reviews of Fisher's data have been published, confirming the original conclusions—namely, that mastectomy, lumpectomy, and lumpectomy with radiation provide comparable survival advantage.²⁶

OUTMODED IDEAS AND PRACTICES

It is becoming clear that the Halsted mastectomy was based on an outdated model of breast cancer. Fisher²⁷ revised the model after years of clinical trials, concluding that

cancer is a systemic disease involving a complex spectrum of host-tumor interrelations and that variations in local-regional therapy are unlikely to substantially affect survival. All of the findings ... did not conform to the concepts that served as the basis for the principles of the Halstedian hypothesis but, rather, provided a matrix for the formulation of an alternative thesis, which is biologic, rather than anatomic and mechanistic, in concept. Its components are completely antithetical to those of the Halstedian thesis.

Fisher further clarified some misconceptions regarding who is eligible for lumpectomy. Tumor size or location does not preclude saving the breast by use of lumpectomy. Large tumors can often be shrunk by preoperative chemotherapy. Women with lymph nodes that are found to have (positive) or not have (negative) cancerous cells are equally eligible. Age is also not a factor—lumpectomy is equally appropriate for older and younger women. Finally, there is the issue of patient choice, and a woman's preference for mastectomy. To this Fisher²⁷ says, "Patient autonomy will not be compromised and paternalism will not be resurrected if physicians firmly inform patients that, in almost all cases based on current knowledge, mastectomy is no longer justifiable, and lumpectomy followed by breast irradiation will not put them at greater risk of developing systemic disease or of dying than mastectomy would." Fisher's reanalysis and results were published in a 1995 report. He found that upon evaluation of three treatments (simple mastectomy, lumpectomy with irradiation, and lumpectomy alone), an average of 60% of patients were alive after 12 years and about 50% had no tangible signs of disease.²⁶

To account for the discrepancy between the research

supporting lumpectomy and the persistence of its lack of use, Harvard professor of surgery William Silen²⁸ laments the replacement of data by dogma. "One of the best examples of this," Silen says, "is the use of the Halsted radical mastectomy for breast cancer." He identifies several problems, beginning with residency training when the young doctor is indoctrinated into managing situations in the "usual manner because that's the way we've always done it. Such normative behavior is expected to occur automatically and without question." He continues: "Beyond the period of training, surgical practice is strongly influenced by the leaders of the profession who are not always meticulously scrupulous in attention to the validity of the material they publish." He chastises the profession to more accurately assess the outcomes of what it does.²⁸

Although remuneration for mastectomy is more than triple that of lumpectomy, financial motives do not account for the hegemony of this procedure. Habits and tradition assume an authority of their own. Is it reasonable to liken surgeons, men or women, to the tribal Africans who perform clitorectomies with the unshakable conviction that they are acting in the best interest of the woman? In both instances, what is best for the woman is associated with maintaining conformity with an outmoded belief. It is neither the women nor the doctors who are to blame; both come to the matter with honorable intentions. Cultural forces conspire: professional recommendations conflict, an irrational fear of keeping the breast is planted in women, and mastectomy constitutes a conclusive sacrificial act that permits women to feel as though they are doing *everything* they can.

Mastectomy itself is not difficult, nor does it constitute a serious risk. Perhaps it even serves as a form of penance for women who unconsciously feel that they have been bad enough, or foolish enough, to have contracted the disease in the first place. It appears to be the very least they can do to neutralize the offending body part, to cast it, along with some small measure of their fear, aside. Upon encountering the dreaded words of the doctor, "I'm sorry, the mass is malignant," a woman can be overcome by waves of shock, succeeded by an avalanche of terror, followed by the resolve to beat this disease. It is not uncommon for a woman to respond with offensive resolve, asserting, "I want it out."

Yet in 1951 Scotsman Wallace Park and Englishman James Lees²⁹ theorized that treatment has little, if any, influence on the natural history of the disease, maintaining that the type of tumor and its biology are determinant.^{29,30} It is curious that in Europe there has been less resistance to this view than in America.

There has yet to be a modern prospective randomized trial of how women fare with and without treatment. There was, however, a unique study of 250 untreated women between 1805 and 1933 at Middlesex Hospital in London, where women were diagnosed without benefit of mammography—only by the naked eye or palpation of a mass. Middlesex, founded as a hospice for cancer patients in 1792, housed only women with extensive and measurable disease. According to an analysis comparing the Middlesex patients with those treated by Halsted, the untreated women did about as well as those who received the Halsted mas-

tectomy between 1889 and 1933 (note 8). Many did as well as women today who obtain the most advanced therapies.

Highly regarded medical oncologist Craig Henderson, formerly of Harvard's Dana Farber Cancer Institute and the University of California–San Francisco's Breast Cancer Center, uses the Middlesex patients as an example. "The median survival time of the untreated patients was 2.7 years," he says, "and several patients lived almost two decades without treatment after the first symptom or sign of cancer in the breast. The survival of treated patients in the earliest radical mastectomy series was not very different ... [and] strikingly similar to that of this subset of American patients with apparently aggressive disease whose tumors were diagnosed and treated more than a century later" (note 9).

Nancy Evans of Breast Cancer Action—herself diagnosed with breast cancer 7 years ago—points out that, as with people diagnosed with HIV, it is unlikely that breast cancer is a curable disease, despite the reality that many women live with it a long time, dying finally of other causes (note 10). In patients followed for 20 to 30 years after initial diagnosis and treatment, 75% to 85% showed some evidence of tumor persistence at the time of death.³¹ Although "the earliest possible diagnosis" is sometimes helpful, it is not necessarily so.

The notion of a "cure" can be misleading, implying that we are fixed, inoculated against death, our existential state of impermanence magically remedied. There are several different medical uses of the term "cure." Clinical cure refers to a 10-year period in which there are no known symptoms and no known recurrence. Statistical cure means that a woman diagnosed with breast disease has the same *relative* survival chances as does the normal population—even though she may die "of" or "with" her tumor. Biological cure means that there is no evidence of malignancy at autopsy (verbal communication, Nat Berlin, MD, February 1996).

POPULAR CONCEPTIONS REVISITED

Today popular conceptions of breast cancer and its management are becoming outmoded as research exposes their lack of merit. Unfortunately, instead of this leading to the modification of common medical procedures, or to the understanding that these protocols are becoming obsolete, many persevere unchanged. Some of the tenets accepted as gospel need revisiting—not only the mastectomy, but also the classification of ductal carcinoma *in situ* as cancer, the misconception surrounding "early detection," axillary lymph node dissection, radiation following surgery, and intensive postsurgical follow-up (chest x-ray and bone scans), as well as one of the newer therapies—high-dose chemotherapy with bone marrow or stem-cell transplant.

There is not unanimous agreement about what constitutes breast cancer. Breast anatomy may be helpful in understanding how the disease is defined. Breasts house a series of milk-producing glands that empty into smaller and larger tubes called ductules and ducts. Put simply, breast cancer means uncontrolled growth of cells—tissue that, when removed and analyzed by a pathologist, shows that malignant cells have overrun the anatomical boundary of the duct and extend into the surrounding tissue.

The most common form of breast cancer, referred to as “infiltrating ductal carcinoma,” comprises 70% to 80% of invasive tumors that arise within the mammary ducts and invade the surrounding fatty tissue (called the stroma). The other 20% to 30% are subtypes (invasive lobular, medullary, mucinous, tubular, adenocystic, papillary, carcinosarcoma, inflammatory). This scheme of classification is based on locale and behavior. Americans might be differentiated geographically—as New Yorkers, Southerners, and Californians—but there are plenty of variations within each regional type.

Breast cancer is not a single disease, but an umbrella term for a plethora of diseases. It is no more homogeneous than infectious diseases—mumps and malaria have as little in common as herpes and cholera. Similarly, breast cancers differ strikingly from one another. Within each tumor itself there is enormous heterogeneity. Tumors are as diverse biologically as Manhattan is socially. A tumor is not composed of a single type of cell. It is like a vegetable basket that contains bits of lettuce, carrots, beets, broccoli, and zucchini indiscriminately fused together. Each vegetable has a unique shape, texture, growing pattern, and chemical composition. A tumor is a biological entity unto itself—like the city of Manhattan—yet the inhabitants of the city neither look alike nor behave, eat, or recreate uniformly. Some tumor cells metastasize early; some never do; others do so slowly. Some are accelerated by estrogen; others are not. Some encourage blood vessel growth; some do not. These processes are determined by the genetic material within the myriad cells that comprise the tumor. Even though it may be reasonable to say that two women have breast cancer, when the disease in the two women is compared, there might be so many differences that one begins to question whether they truly do have the same disease. Rate of growth and infiltration may take 3 years in one woman and 40 years in another.

Ductal Carcinoma In Situ Classification

Some abnormalities look like cancer under the microscope but do not act like it, and therefore are not truly breast cancer. One of these discrepancies between anatomy and behavior is “ductal carcinoma in situ” (DCIS), which consists of an abnormal proliferation of ductal cells that do not invade the basement membrane of that duct (hence the term “in situ,” meaning “confined to the site”). Because DCIS does not extend beyond the borders of the duct, it is noninvasive, and does not therefore constitute a true malignancy. In 1934 Halsted’s former resident, Joseph Bloodgood,³² described DCIS as precancerous tissue—a depiction that still applies.

Richard Margolese, surgical oncologist at McGill, says, “The management of ductal carcinoma in situ ... is controversial. It is not clear whether all carcinomas are preceded by DCIS or if all DCIS leads inexorably to carcinoma.... A better understanding of the biology of DCIS would lead to better clinical management.”³³ Because of the confusion surrounding the sequelae to DCIS, many current breast cancer studies include women with DCIS, because they regard it as a malignancy; thus the outcomes

of these studies are skewed. According to William Silen of Harvard, “Twenty-five or thirty years ago, it was taught that there was no such thing as noninvasive carcinoma of the breast. In pathology, I was taught that if you looked far enough, you’d always find invasion. I’m absolutely convinced that a lot of the so-called cures achieved with radical mastectomy were patients who actually had noninvasive carcinomas of the breast.”^{33(p358)} Unfortunately, the language does not change appropriately every time the explanatory model shifts. Understandably, this causes confusion. The term “carcinoma” is used both to define malignancy and to describe tumors that are not malignant by virtue of the fact that they neither invade nor spread.

Early Detection

Public misconception abounds concerning the concept of “early detection.” It is perhaps the most mystifying oxymoron within the vocabulary of the breast cancer paradigm. What is early? Ideally, it is before the local malignancy has spread, or metastasized. Although it’s a difficult notion to accept, there is no way of knowing whether malignant cells have spread by the time of detection. Frequently the term “early” is confused with the term “small.” Generally a small lump is preferable to a larger one—but this is not always the case. The significant determinant is biological: whether the cancer has infiltrated beyond local boundaries, how fast it is growing, and where it is growing.

It is known that it takes an average of 10 years for a tumor of the breast to grow to 1 cm (a little less than half an inch) in diameter. It is hypothesized by Judah Folkman³⁴ of Harvard that as the number of blood vessels supplying the tumor increases, so does the likelihood of metastatic disease. It is not known precisely how long it takes for tumors to acquire an adequate blood supply. It takes approximately 5 years from the time a cell becomes malignant (ie, shows evidence of uncontrolled growth) to the time that it develops enough vasculature for tumor cells to enter the bloodstream. One cubic centimeter of breast cancer tissue contains roughly one billion cells. Based on the doubling rate of cells, it takes 30 replications for one cell to become one billion. If the time of replication is 120 days, then there are 3 replications per annum, so over a 10-year period there are 30 replications. It is thought that in the first 5 years (half of the hypothesized 10-year period), the mass is not sufficiently vascularized (does not have an adequate blood supply) to be able to metastasize. But a palpable mass—or one visualized on mammography that is 1 cm in diameter or more—may have been growing for 10 years. By this stage it has likely become bloodborne and widely disseminated. Local treatment—mastectomy, lumpectomy, or radiation—will not have any impact on survival if malignant cells have been seeded elsewhere (note 11).

Breast surgeon Susan Love,³⁵ testifying before the Senate in 1991, stated that

[w]e have spent a lot of time, energy, and money touting *early detection* and preserving it as if it were the answer. Unfortunately, we have misrepresented the situation

through wishful thinking or just an attempt at simplification. We have acted as if all tumors go through progression from one centimeter to two centimeter[s] and on and on as if all tumors have the potential to be detected at a small size and therefore could be cured. Would that were true. What we are dealing with is a combination of a tumor and an immune system. Some tumors are very aggressive and will have spread before they are palpable. Thirty percent of [the women with] nonpalpable tumors are found to have positive lymph nodes. Some tumors are very slow growing and will not have spread even though they have reached a large size (note 12).

The value of “early detection” is complicated by a factor called “lead-time bias.” Namely, women *appear* to live longer when the disease has been identified earlier, but mortality has not necessarily been affected. There is a widespread collective misunderstanding that if only the lump is found “early,” the problem can be either aborted or “fixed.” This has led to false guilt on the part of women who feel that through their negligence they are responsible for their misfortune, false blame toward doctors even though they could not have discovered the lump sooner (and even if they had, it would not have mattered), and anguish at a cost of millions of dollars in litigation without sound medical foundation.

Not only is the notion of “early” muddled, but the question of *what is being detected* is also difficult to grasp.³⁶ Nearly one third of the women with tumors undetected by mammogram have positive lymph nodes—a sign that the disease is already systemic.³⁷ Mammography fails to detect one fifth of all cancers; in women under 50, it misses as much as 40%.³⁸ Unfortunately, having a clear mammogram does not mean that a woman is cancer-free. But because many cases are visualized by mammography, the current recommendation is that, especially for women over 50, it is a useful tool—particularly when a qualified technician uses a reliable mammography machine with a skilled radiologist interpreting the results. As counterintuitive as it sounds, radiologists Samuel Hellman and Jay Harris³⁹ assert that “[d]etection of cancer at an earlier stage does not necessarily imply an improved cure rate.”

Axillary Node Dissection

Axillary node dissection is another procedure that is no longer routinely justified, yet remains firmly entrenched. Halsted was wrong: cancer does not spread in an orderly fashion via the lymph system, node by node. Whether nodes are positive or negative does not necessarily foretell whether an individual woman will have a survival advantage. An early hypothesis posited that the presence of malignancy in the lymph nodes served as a marker for who should receive chemotherapy. But new studies have shown that it is not an accurate prognostic measure. In 1986, Hellman and Harris³⁹ reported the following: “Twenty-five percent of patients without axillary lymph-node involvement develop metastases while 25

percent of those with axillary lymph-node metastases never develop distant metastases.” Thirty-eight percent of women with negative lymph nodes die of the disease, which demonstrates that the positive or negative status of these nodes does not provide reliable prognostic information.

Harvard surgeon Blake Cady urges that “[w]e need to move beyond the latest dogma and convention regarding routine axillary dissection for established functionally equivalent goals” (note 13). In a book called *Important Advances in Oncology 1996*, Cady writes a chapter titled “Is Axillary Node Dissection Necessary in Routine Management of Breast Cancer? No.” Surgeon Peter Deckers suggests that “[w]ithin the next decade, axillary dissection will be extinct.”^{33(p360)} Again, it is the cellular biology that is most crucial in determining prognosis and treatment, and this is now the focus of current research. But there is a lag time between the incorporation of new information and the dispatch of old habits.

Fisher’s Protocol B-04 study established that axillary node dissection does not provide survival benefit. When further treatment was dependent on whether the nodes show malignancy, then node dissection was perceived to be a useful procedure. Today, however, we have many biological markers that provide information equivalent to positive or negative node status, rendering this procedure obsolete. If these markers suggest that a tumor is aggressive, women will receive chemotherapy regardless of the status of their axillary nodes. The medical school dictum applies: “If the results of a test do not change what you do, do not do the test.” So why does it continue as routine procedure? Again, one suspects a lag between habit and the adoption of the newer logical thinking. When queried, many oncologists say, “I just feel more comfortable knowing about the nodes.” But unless there is good justification for axillary node dissection, it should be questioned because it does harm.

Lymph node dissection is not only expensive, it disables thousands of women unnecessarily. For example, a woman named Dana had a mastectomy accompanied by removal of the lymph glands under her arm 8 years ago. In some women, the fluid that would normally drain through the lymph channels backs up, causing swelling (lymphedema). Aside from the limited use of her shoulder and limb, Dana suffers from bouts of cellulitis, infections that sometimes arise from mosquito bites or scratches, requiring her to be on long-term antibiotic management to prevent blood poisoning (septicemia). About 20% of the women who have their nodes removed develop measurable lymphedema (note 14).

Some oncologists recommend a bone marrow transplant if more than 10 nodes are positive. But the value of adjuvant bone marrow transplantation has not been established.

Lymph nodes were once thought to be the instigators of disease, the source of metastatic dissemination. According to Virchow, malignancy, like the tubercle bacillus, traveled through the lymph channels and proceeded in an orderly, mechanical fashion from the local site, progressing to the glands under the arms, and from there migrating to distant sites. We now know, contrary

to Virchow's theories proposed a dozen decades ago, that the proliferation of malignancy is neither orderly nor mechanical.

Radiation

Radiation is a known carcinogen that can produce irritable, red, inflamed tissue in the short term; and stiff, thickened, desensitized tissue over time. Radiation following lumpectomy has no proven impact on survival, though it does affect local recurrence. Women who recur have an increased mortality, not because of the local tumor, but because recurrence is the manifestation of biologically more aggressive disease. Recurrence, however, is only symptomatic of increased risk of metastases, *not* the cause of the disease's spread. Removing the possibility of recurrence no more enhances a woman's health than removing the speedometer of a car alters its speed.

In rural areas like the outlying plains of North Dakota, where women must travel 6 or 8 hours to receive radiation therapy, mastectomy has been recommended over lumpectomy to prevent local recurrence. But women who do not receive radiation following lumpectomy have the same chance of survival as those who do.^{26,40,41} The only difference is in the likelihood of local recurrence: 40% of women who do not receive radiation therapy will have a local recurrence within 10 years, whereas 15% who have had radiation following their lumpectomy will have a local recurrence within 10 years. It seems difficult for us to comprehend that how long a woman lives is not dependent on whether the local disease returns. It is not local disease that is life threatening, but the rapidity with which metastatic disease proceeds—something that there is no way to predict as of yet.

Women who recur within 2 years have a 20% chance of living 10 years, whereas women who recur after 5 years have the same chance of survival as those who do not. Recurrence within 2 years may serve as a more valuable marker of disease progression than any other.⁴² It was shocking when Fisher's study⁴⁰ demonstrated that local recurrence did not impact survival. Yet doctors seldom make this clear to patients.^{38(p74)} Because the value of radiation is questionable, its role following lumpectomy is currently under scrutiny.

Intensive Follow-Up: Chest X-Rays and Bone Scans

The effort to secure medical certainty is costly, elusive, and usually futile. Because elite medical schools are swollen with prestige, power, and funds, and because their libraries bulge with data, there is a public illusion that medicine is equipped to remedy our complaints. Because people think their doctors are so smart, they find it impossible to believe that they don't know how to help. People want prognostic and diagnostic as well as therapeutic answers.

The belief that an earlier detection of recurrence leads to a higher likelihood of disease control, complete remission, or at least extended survival has led to intensive routine surveillance programs. It now appears that such ardent follow-up screening (chest x-ray and bone scan) for asymptomatic women is a costly measure that has wide acceptance but limited value. Usefulness

is a judgment measured by the criteria of quality of life and survival benefit. The early detection of distant metastases has shown no survival advantage. Chest x-rays have not been particularly useful in detecting recurrence, nor has bone-scan surveillance been fruitful in asymptomatic patients.⁴³ After a review of several studies, the following conclusion was reached by Roselli Del Turco et al⁴⁴: "Periodic intensive follow-up with chest [x-ray] and bone scan should not be recommended as routine policy."

Chest x-rays were instituted as a public-health protection against tuberculosis: their routine use is considered an expensive and outmoded practice by many. On the other hand, follow-up with a physical exam twice a year and a yearly mammogram are both sensible and cost effective. According to Charles Loprinzi⁴⁵ of the Mayo Clinic, "retrospective studies ... do not suggest that patients who had routine follow-up testing did any better than those patients who did not.... A history and physical examination are clearly the best methods for obtaining evidence of recurrent breast cancer. Several studies have reported that 75% to 85% of recurrences are detected this way (even when frequent additional tests are performed)."

Every time Lyra, a 52-year-old woman who had a mastectomy 4 years ago, feels an ache in her calves, she worries. She anticipates bone scans every few months with equal parts dread and hopeful expectation. The usefulness of this intensive surveillance ritual is more than questionable. Metastatic bone disease rarely remains asymptomatic for more than 3 months. If Lyra's bone scan is negative, it simply means that the part of the bone scanned did not show evidence of disease. If it is positive, there is little advantage in knowing this before actual symptoms of the disease arise. Most bone metastases will become symptomatic within 90 days. Greater power is attributed to diagnostic instruments than is often warranted—scans are imperfect devices that offer relatively crude measurement. Technology has advanced more rapidly than our understanding of how to derive benefit from it.

A savings of \$636 million in the United States for the year 1990 was projected for the minimalist surveillance protocol (history, physical exam, mammogram) over the more intensive series (physical exam, blood cell count and chemistry, antigen level, mammogram, chest x-ray, bone scan) currently in routine use.⁴⁶ By the year 2000, the cost savings is estimated to be \$1 billion. Again, science can only dubiously cater to the best hopes of patients *and* doctors. Researchers comment: "In conclusion, although the patient and physician may have an intuition that intensive surveillance will detect recurrence earlier and prolong survival compared with minimal surveillance, this feeling is not borne out...."⁴³ In 1990 breast cancer consumed \$6.5 billion—more healthcare dollars than any other cancer. After an exhaustive assessment, Herman Kattlove et al^{37(p142)} concluded, "Regrettably, it is easier to estimate the expense of medical care than to project the benefit."

Bone Marrow or Stem-Cell Transplant

In 1995 an independent technology-assessment organization conducted a thorough review of studies, concluding that

there is no evidence of any prolonged disease-free or overall survival benefit from the use of either bone-marrow or stem-cell transplants compared with conventional chemotherapy under any circumstances. Reimbursement for these therapies is controversial, and breast cancer patients are seeking insurance coverage ranging between \$50,000 and \$200,000 for this therapy. Several states have mandated such coverage. This is perhaps another example of both doctors and patients wanting to believe that if a little is good, more must be better. But 31 studies between 1984 and 1994 showed either no improvement or slightly increased early death rates. Substantial evidence of harm exists for these therapies (note 15).

MAKING SENSE OF WHAT WE KNOW: POPULAR INTUITIVE ASSUMPTIONS VS COUNTERINTUITIVE EVIDENCE

An advertising concept called “positioning” refers to securing a place for a product in the consumer’s mind that, ideally, will become identified with the function served. Examples of this are the brand Kleenex, which has become synonymous with tissues, and Xerox, which has become a verb for photocopying. Analogously, the paradigm for the mechanical spread of breast cancer has become fixed securely within doctors’ minds, and “removal before it spreads” has become the corollary knee-jerk response. The delusion lingers that if enough malignant tissue is excised, then the cancer can be evicted and the patient cured.

Prior to and in the absence of prospective, randomized, controlled, double-blind studies, treatment protocols are inevitably the fruit of speculative clinical postulates to be tested over time. This holds true for regimens of chemotherapy, radiation, and surgical procedures. When clinical studies throw those habitual behaviors into question, rather than behaviors adapting, studies are often functionally disregarded. Perhaps this is because habits have encouraged theories to be mistaken for facts. It is within this context that the the Office of Technology Assessment issued a report stating that only 17% to 20% of conventional medical practices are based on scientifically validated evidence, and that 80% to 83% are based solely on anecdotal data (Office of Technology Assessment, US Government Printing Office, Washington, DC; 1988).

For example, it was hypothesized that positive axillary nodes served as a predictor for the spread of the disease. When evidence indicated otherwise, only a few doctors altered their clinical behavior. Similarly, bone scans, chest x-rays, and blood work have been shown to be of little use, yet more than half a billion dollars are spent each year when a physical exam, history, and mammogram are sufficient. Even though radiation following surgery reduces local recurrence, it is clearly established that the reduction of local recurrence does not impact survival. Radiation following surgery is akin to the ancient Greek custom of killing the messenger who has delivered bad news. Still, only a few physicians perform lumpectomies without recommending radiation therapy. Finally, though mastectomy is popularly perceived to be the safest treatment, there is comparable survival

benefit between mastectomy, lumpectomy with radiation, and lumpectomy alone—women live the same length of time regardless of which intervention they or their doctor choose. Neither mastectomy nor radiation eradicates the possibility of recurrence—they merely reduce it, and local recurrence itself does not suggest that a woman’s chance for a long life is less. Thousands of women and their doctors nevertheless elect mastectomy.

Another major assumption now under question is that people can be separated into two groups: those with metastatic disease and those without. Many leading oncologists now believe that at the time of detection, breast cancer is systemic. In this case, mastectomy plays no role in increasing survival. For the smaller group of women in whom the disease may not be systemic, breast-conserving surgery will remove the local tumor. Finally, when a woman learns that she has breast cancer, and that there is a large probability the disease is systemic, this does not automatically mean that she will die soon. Roughly 50% to 60% of these women will survive, many for decades. The significant features determining longevity appear to be the biology of the tumor and the resistance of the host.

TIMES CHANGE ... AND REMAIN THE SAME

Craig Henderson put it simply: “We’re all prisoners of our oncogenes.” He has taken a leave from clinical medicine to work with molecular biologists in the private sector. Molecular biology is now at the hub of inquiry, prompting a review of customary protocols by some, though the bulk of practice remains the same. At the conclusion of a 1994 symposium of carcinoma of the breast, Marvin Gliedman^{33(pp351-362)} of Albert Einstein College of Medicine queried, “I wonder if breast cancer is a surgical disease any more.” Samuel Hellman and Ralph Weichselbaum⁴⁷ of the University of Chicago say that “[b]ecause of the importance of systemic metastases and the current emphasis on treatments for systemic disease, one may question whether as a regional treatment radiation oncology, like surgery, will have an increasingly restricted role in cancer management.”

Concerning the state of chemotherapy today, oncologists Albert Deisseroth and Vincent DeVita⁴⁸ of the Yale School of Medicine have commented that the most important findings of the last 30 years have been that drugs could cure some forms of cancer—namely leukemias, lymphomas, and some epithelial cancers. They call it both perplexing and disappointing that 90% of all drug cures occur in only 10% of cancer types. Although it was first thought that cancer cells grow more quickly than do normal cells, this has turned out not to be the case. Instead, cancer is caused by a failure on the part of the cell: instead of deciding to divide, it should, for the sake of the organism, choose to be dormant.⁴⁸

Molecular biology, trumpeted by some as the next great frontier of hope, examines the metabolic pathways that constitute the biochemical basis of all life. Molecular answers are being ardently pursued in order to solve the riddle of why cancer occurs. Life is dependent on proteins, which are themselves a string of amino acids. One focus of this biochemical inquest is

upon the regulatory proteins responsible for cell division. This is because cancer is understood as the proliferation of cells without restriction. Somehow the proper regulatory mechanism has been disabled when cells are replicating wildly. It is believed that the coding of the DNA determines the composition of amino acids, which in turn shapes the protein in any given tissue. This DNA is the repository of the genetic code of the organism—that which is passed on to propagate the species and prescribes *who someone is* structurally and functionally. Part of the DNA is wound tightly and part is unwound. When certain proteins become inappropriately unwound, it is thought to produce uncontrolled cell division. The expectation is that manipulation of these proteins may produce a shut-off valve for the carcinogenic process.

It is remarkable that for all our progress in medicine, a *JAMA* article⁴⁹ from 1895 reads as though it were from a current journal describing contemporary practice:

[T]he widespread and increasing prevalence of cancer of the breast, its painful and terrifying features, and, above all, the very great attendant mortality, render it one of the most important of surgical conditions and one in which the most strenuous effort should be made to cure.... Operations for cancer of the breast are designed to be curative or are merely palliative, and it is needless to say that the end in view is determined by the extent of the neoplasm.... [M]ammary cancer is a curable disease, and ... the keynote to its successful management is to be found in the earliest possible diagnosis, prompt and wide excision and careful observation of the patient during the remainder of her life.

How problems are framed determines which solutions are delivered. In answer to the question, “How can local recurrence be eliminated?” one course of therapy—mastectomy—is mandated. If one asks, instead, “What is the least invasive therapy, will do the least harm, and provide equivalent survival advantage?” another intervention is pursued—lumpectomy. If the question is “What environmental, dietary, hormonal, or genetic factors, if any, contribute to the disease or its amelioration?” this launches the investigator onto other trajectories, such as chemical pollutants that are carcinogenic (some because they mimic estrogens in the body), or fatty diets that appear to increase risk, or genetic predispositions. And if a breast cancer is classified according to its growth rate or the type of cells present, this leads in still another direction—one that does not treat all breast cancers equally, classifying them by many different criteria. Patients have the right of treatment choice, but most women are so poorly informed that they cannot choose wisely.

PERSONAL STORY AS METAPHOR: MEDICINE AS SAVIOR OR SLAYER

I grew up listening to my father talk about work around the dinner table. Invariably in the middle of a bite of mashed potatoes and green beans, he was summoned to the emergency room

to repair the fractured femur and lacerated calves of a teenager whose Harley had slid in the sand. At 10, squeezed onto the end of a bench next to a mammoth high school athlete, I'd watch my father trot onto a muddy New England football field, crunchy with frost, his trench coat flapping behind him like wings. One evening after chocolate pudding, eyes shining with zeal, he described new surgical staples that made it possible for him to close bowel resections twice as fast. Often he worked tirelessly into the night while we were asleep. Although usually an energetic optimist, sometimes he'd surprise me with grouchy, venomous criticism. Later, my mother would whisper discreetly that it wasn't me—that my father had a patient sick with pancreatic cancer and he was desolate because there was nothing he could do. I observed first-hand his distaste for powerlessness in the face of irremediable disease.

Although completely devoted to the practice of his craft, my father was a reluctant patient. At 69, he needed to have cataracts removed but stalled for several years, eventually trading the benefits of improved night vision for his diffidence. Opening his closet door, he was amazed to find that all his suits weren't the monotone grey he had perceived before the surgery. It was awesome to me that after spending his life wielding the scalpel, he was so wary of it himself.

Some of his cautious hesitation was transmitted to me. When our son was born 22 years ago, with two gaping holes in a distended heart, we deliberated ambivalently about the cardiologist's urgent plea to go forward with open-heart surgery. Without it his life would have been severely compromised; with it he had a fifty-fifty chance of surviving the surgery. Now the Dacron patches stitched carefully in place by Paul Ebert when our son was 8 months old have enabled him, like the normal kids I envied when he was small, to attend college.

Two years ago I urged my niece, Sherifa Edoga, just after she had graduated with double honors from Stanford, to seek counsel from my son's cardiologist. She was born without a pulmonary artery, the vessel that carries blood from the heart to the lungs to receive oxygen. Always breathless, her lips and fingernails were permanently stained the color of blackberries, a sign of hypoxia—not enough oxygen in the blood. For anyone else it would be a 2-minute jaunt to the car, but she moved like a snail and for her the trip took 20 minutes. It was with trepidation that Sherifa decided to undergo surgery; she had had two operations as a child that had failed. But the able surgeon felt he could help. In the days before, Sherifa made great gains in quieting her fear. She died 5 days after the operation.

My father always characterizes medicine as an evaluation of the lesser of evils, requiring a cost-benefit analysis accompanied by a willingness to gamble. His awareness of doctor-induced problems (iatrogenesis) led us to be apprehensive about both drugs and procedures. Medicine can mean miracles. It can do harm. Doctors want to ply their trade to the task of genuinely serving, and patients yearn to be saved. Ultimately it is we, not our doctors, who must navigate our vessel. It is our destiny that lies on the shore.

LIVING WITH DISEASE

In 1995, eight million new cases of breast cancer and 3 million deaths were recorded worldwide. Breast cancer is the most common form of cancer in women in the United States, the leading cause of cancer death for black women, and the second leading cause of cancer death for women aged 35 to 54 years. Eighty percent of women diagnosed with it are over the age of 50. More than 70% of cases occur in women without any identifiable risk factors. More than 1.6 million women diagnosed with breast cancer are alive in America today, and the 5-year survival rate is over 90% (written communication with National Alliance of Breast Cancer Organizations, March 1996). We are always looking toward future progress, toward what's new that will miraculously transform our capacities for medical management. By looking backward as well as forward, we gain insight, if not the ever-elusive cure.

Poet Lucille Clifton⁵⁰ writes:

we are running

running and
time is clocking us
from the edge like an only
daughter.
our mothers stream before us,
cradling their breasts in their
hands.
oh pray that what we want
is worth this running,
pray that what we're running
toward
is what we want.

Halsted Holman, professor emeritus at the Stanford School of Medicine, is the son of Emile Holman, who, like Cushing, was a protégé of both Osler and Halsted. Named after his father's mentor, Halsted Holman oddly echoes Virchow's social perspective, bringing dialogue full circle. In the middle of the 19th century, Virchow claimed that many maladies were the result of an inequitable distribution of social and economic resources, advocating that doctors should exercise their power to abolish the social conditions that are at the root of so many diseases. Virchow asserted that "[p]hysicians are the natural attorneys of the poor."^{11(p316)} Similarly, Halsted Holman⁵¹ comments:

Longevity has changed little, and the major illnesses such as malignancy and cardiovascular disease remain unimpeded. Illnesses disproportionately affect the poor, major environmental and occupational causes of illnesses receive little attention and less action, and malpractice charges intensify. Clearly, there is a crisis in health care, both in its effect upon health and in its cost. Simultaneously, medical institutions characterize themselves as excellent. Some medical outcomes are inadequate not because appropriate technical

interventions are lacking, but because our conceptual thinking is inadequate.

Medicine cannot capitulate to less than a thorough and ongoing review of its own habits of mind, as well as its practices. On the disappointing results in the treatment of breast cancer, one of Virchow's pronouncements spoken in 1896 is still germane: "Indeed, a great deal of industrious work is being done and the microscope is extensively used, but someone should have another bright idea."^{14(p107)} Psychologist CG Jung⁵² commented that "[t]he serious problems in life ... are never fully solved. If ever they should appear to be so it is a sure sign that something has been lost. The meaning and purpose of a problem seems to lie not in its solution but in our working at it incessantly."

Although breast cancer is always undesirable and bad, the women who have it are often splendid and good. No one chooses breast cancer as a teacher, but it becomes one. Many women struggling with breast cancer are heroic, powerful, and courageous. How each woman chooses to interact with this disease is as varied as the lives they live. Libby was diagnosed 3 years ago and underwent a modified mastectomy and intensive chemotherapy for a year, which eliminated metastatic liver tumors from view on a CAT scan. The tumors recently recurred. Shirley was told, after 3 years of therapy, that she had only 6 months to live without a bone marrow transplant. She decided not to follow this path, went into remission, and was alive 4 years later. Catherine found a lump while lathering in the shower, had a lumpectomy, and elected not to have her lymph nodes dissected nor undergo radiation or chemotherapy, instead exploring alternative therapies including herbs, a careful diet, yoga, and other activities that gave her pleasure. It is now 5 years that she is alive, though she has evidence of local masses. Erica did not survive a bone marrow transplant. Marilyn did. Breast cancer may be lethal, but we know birth to be an absolutely fatal disease. Many women who are diagnosed with breast cancer will die of other causes, even though they do not get over the disease as if it were a winter cold.

Debra's acupuncturist, reflecting on her breast cancer, commented, "You're the sky and the disease is a cloud in the sky." He is aware of the dualistic perspectives that sometimes have difficulty meeting: attention to the disease mechanism versus regard for the person who has it. Put simply, in one model the doctor is a mechanic fixing a broken body machine, and in the other the doctor is a gardener cultivating a healthy ecology in which the rich soil houses microbes that can combat pests. This is another debate that has echoed through centuries. In mid-19th-century France, Louis Pasteur introduced the idea that disease was located outside the body, in the form of germs. This distracted medicine, encouraging people to think that the invaders could be slain like marauders in a castle. Pasteur's contemporary Claude Bernard had insisted that it was the *milieu interieur*—the state of the organism; the relationship between the seed and the soil, the pathogen and its host—that was determinant. Breast conserving pioneer and physician Vera Peters⁵³ comments that "[t]he important influence

of the patient's potential to control her own disease cannot be overlooked. Probably a superior immune mechanism is the major factor allowing the majority to postpone metastatic disease for many years. Their immune potential is reflected by their state of physical and mental health, and by the lymphocyte count."

Cancer exists on a continuum, with endogenous (internal) causes on one end and exogenous (external) causes on the other. Surgeons are the mechanics and oncologists are the pest controllers. Today the focus is on chemotherapy as a form of pest management; tomorrow there is a promise of medicine being equipped to enhance our self-capacities and eliminate virulence through engineering molecular environments.

Others believe that it is the ambient and ubiquitous burden of toxins in the soup in which we swim daily that foments these changes within. Rather than breast cancer being a local problem, it is a global one—it tends not to have a single regional locus, but becomes universal within the organism; it is more like a virus than a fracture. Struggling against disease with hope is itself believed by many to be therapeutic, but there is not enough known to issue universal prescriptions. Over the centuries, even some of our greatest spiritual teachers have died of cancer.

Surgeon Richard Selzer⁵⁴ commented that after he wrote a medical essay titled "The Exact Location of the Soul," readers wrote to him, pumping him for more specific information. Upon reflection he answered that if he were to fix the soul in a location, it would be in the wound, that place of tender suffering. Buddhists claim that life is an evolutionary exercise in learning lessons dressed in suffering. One antidote to suffering is glad acceptance—not wishing for things to be other than they are. This entails transcendence of future-oriented desires and instead focuses on experiencing each moment as bliss: exquisitely full, complete, sufficient. The emphasis shifts to the quality rather than the duration of life—more on living better, and less on living longer. Some studies suggest that women who exhibit optimistic determination fare better than do those who are either helpless and hopeless, or those who are anxiously preoccupied.⁵⁵ Hope can mean tenaciously affirming that life makes sense while encountering the universality of our inevitable death. The best we can do is live well each day, paradoxically accepting what *is* as we strive valiantly to change.

Acknowledgment

The authors wish to thank Nat Berlin, MD, for his valuable comments during review of this manuscript.

Notes

1. The NCI Consensus Conference concluded that "[b]reast conservation treatment is an appropriate method of primary therapy for the majority of women with Stage I and II breast cancer and is preferable because it provides survival equivalent to total mastectomy and axillary dissection while preserving the breast.... Breast conserving treatment [defined as lumpectomy and axillary dissection followed by irradiation] is preferable because it provides survival equivalent to total mastectomy and axillary dissection while preserving the breast" (NIH Consensus Development Panel. Consensus development conference on the treat-

ment of early-stage breast cancer. *J Natl Cancer Inst.* 1992;11:1-5).

2. Greater cohesion and homogeneity of the profession were also achieved by the deliberate segregation of Jews, Catholics, women, blacks, and the foreign-born, consolidating the rise of a genteel Protestant medical aristocracy. Medical school admission and operating privileges at hospitals were granted to a closed fraternity of surgeons, qualified more by social caste than by professional achievement. Discrimination underlay the building of hospitals with names like Saint Vincent, Saint Mary, Saint Joseph, Beth Israel, Mount Zion, Mount Sinai—places that welcomed Catholic and Jewish patients and doctors.^{10(pp173-177)}

3. Establishing Johns Hopkins as the model for all others to follow was consolidated by the Flexner Report of 1910, which forced the massive closure of schools that did not conform to the new standards. By 1936, \$91 million was steered primarily from the Rockefeller General Education Board into a select group of schools, Johns Hopkins being among the seven that received more than two thirds of the funds.^{10(p121)}

4. Curiously, his parents were both the offspring of business partners (his father was a Halsted and his mother was a Haines) and cousins (his mother and father were the children of sisters) (Rutgow I. William Halsted, his family, and 'queer business methods.' *Arch Surg.* 1996;131:125).

5. In London, Charles Moore formulated the principles of mastectomy in 1867; Joseph Pancoast, from Philadelphia, recommended removal of the breast and glands all in one piece as early as 1844; Richard von Volkmann in Germany and Theodor Billroth in Vienna both removed the entire breast in the 1870s; and William Handley in London and Willie Meyer were contemporaries of Halsted, who supported his efforts with their own.

6. Halsted demonstrated the use of cocaine as local anesthesia to Koller's friend, Anton Wollfer, who had been the Viennese surgical giant Theodor Billroth's first assistant. Later, Wollfer published on the subject (Penfield W. Halsted of Johns Hopkins. *JAMA.* 1969;210[12]:2214-2218). (Reprint of Halsted's letter to Osler, dated August 23, 1918.)

7. In a private letter to Osler, Halsted wrote that three of his associates "acquired the cocaine habit in the course of our experiments on ourselves—injecting nerves. They all died without recovering from the habit" (*JAMA.* 1969;210[12]:2217).

8. A lump was the initial symptom in 83% of the women, which by the time of hospitalization had become a large mass for many. Ulceration, sometimes extensive, was seen in 68%; only 7% of the women came to the hospital within 6 months of the symptoms. Seventy-one percent delayed for more than 12 months. In 24% of the women, more than 3 years elapsed; in 12%, more than 5 years. The longest delay was 16 years. This contrasts with later practices, in which patients present within 6 months to 1 year after symptoms are noticed. A high percentage of the Middlesex women therefore had advanced disease (Bloom H, Richardson W, Harries E. Natural history of untreated breast cancer [1805-1933]. *Br Med J.* July 1962:219). According to Diana Fischer, research scientist at Yale School of Medicine, the 50 women who received mastectomies reported upon in Halsted's study between 1889 to 1894, when compared with the 250 cases at Middlesex Hospital in London between 1805 to 1930, showed no statistically significant survival difference between the surgically managed and untreated women (written communication, March 1996).

9. Farber D. Biologic variations of tumors. Presented at the American Cancer Society; October 11-13, 1991; Pasadena, Calif (referring to Bloom H, Richardson W, Harries E. Natural history of untreated breast cancer [1805-1933]. *Br Med J.* July 28, 1962:213-221).

10. "For virtually all patients who have had a mastectomy, recurrent breast cancer is not a curable disease" (Loprinzi C. It is now the age to define the appropriate follow-up of primary breast cancer patients. *J Clin Oncol.* 1994;12(5):881. Editorial).

11. If in 10 years there are 1000 cells within a tumor, in 20 years there are 1 million; in 30 years, 1 billion; and in 40 years, 1 trillion. The human body contains about 11 trillion cells. Death usually results when 10% of the body is replaced by cancer cells. The doubling time of breast cancer cells varies greatly—from 9 to 900 days, with an average being 100 to 185 days (Spratt JS, Spratt JA, *Growth Rates in Cancer of the Breast.* 3rd ed. Philadelphia, Pa: WB Saunders; 1988:270-302).

12. Love comments elsewhere: "I think that any breast cancer large enough to be detected has already spread.... The danger of cancer depends on the balance between the cancer and the ability of your body's immune system to fight it" (*Dr Susan Love's Breast Book.* Reading, Mass: Addison-Wesley; 1990:212).

13. "Whether lymph node metastases in the axilla or internal mammary drainage basins are removed, radiated, or merely observed, survival is absolutely equivalent" (Cady B. Dilemmas in breast disease. *Breast J.* 1995;1[2]:121-124).

14. The National Lymphedema Network, based in San Francisco, and Stanford University are each testing an early therapy for the problem using massage, special armbands, and lifestyle modifications, though elimination of the procedure would absolutely cure the side effects of lymph node dissection.

15. High-dose chemotherapy with autologous bone marrow transplantation and/or blood cell transplantation for the treatment of metastatic breast cancer. Executive Briefing, Emerging Care Research Institute (ECRI), February 1995. ECRI is an independent technology assessment organization located in Plymouth Meeting, Pa. An article about ECRI appears in *JAMA* (1995;274[13]:999-1001).

References

1. Boring CC, Squires TS, Tong T. Cancer statistics—1993. *CA: Cancer J Clin.* 1993;43(1):7-26.
2. American Cancer Society. *Cancer Facts & Figures—1992*. Atlanta, Ga: American Cancer Society; 1992:3.
3. Halsted WS. The results of operations for the cure of cancer of the breast performed at Johns Hopkins Hospital from June 1889 to January 1894. *Johns Hopkins Bull.* 1894-95;4:297-350.
4. Baum M. Breast cancer: lessons from the past. *Clin Oncol.* 1982;1(3):650.
5. Fisher E. The impact of pathology on the biologic, diagnostic, prognostic, and therapeutic considerations in breast cancer. *Surg Clin North Am.* 1984;64(6):1073.
6. Papaioannou A. Systemic therapy as the initial step in the management of operable breast cancer. *Surg Clin North Am.* 1984;64(6):1181-1191.
7. Papaioannou A. Increasingly intensive locoregional treatment of breast cancer may promote recurrence. *J Surg Oncol.* 1985;30:33-41.
8. McNamara R, Vandemark B. *In Retrospect: The Tragedy and Lessons of Vietnam*. New York, NY: Random House; 1995.
9. Latour B, Woolgar S. *Laboratory Life: The Construction of Scientific Knowledge*. Princeton, NJ: Princeton University Press; 1986.
10. Starr P. *The Social Transformation of American Medicine*. New York, NY: Basic Books; 1982:82-83.
11. Nuland SB. *Doctors: The Biography of Medicine*. New York, NY: Vintage; 1989:365-385.
12. Rutgove I. *Surgery: An Illustrated History*. St Louis, Mo: Mosby; 1993:448.
13. Holman E, Osler and Holsted, a contrast in personalities. In: McGovern JF, Burns CR, eds. *Humanism in Medicine*. Springfield, Ill: Charles C Thomas; 1973:25.
14. De Moulin D. *A Short History of Breast Cancer*. The Hague, The Netherlands: Martinez and Nijhoff; 1983:53,75.
15. Carter BN. The fruition of Halsted's concept of surgical training. *Surgery.* 1952;32(3):518-527.
16. Gerrish F. Adenocarcinoma of the breast. *Trans Am Surg Assoc.* 1898;16:163-165.
17. Halsted WS. The results of radical operations for the cure of cancers of the breast. *Ann Surg.* 1907;46(1):1-20.
18. Matas R. Adenocarcinoma of the breast. *Trans Am Surg Assoc.* 1898;16:168.
19. Dowling H. *Fighting Infection: Conquests of the Twentieth Century*. Cambridge, Mass: Harvard University Press; 1977:77.
20. Weiss S. Influences of American philosophy and history on the practice of American medicine. *Conn Med.* April 1995: 227.
21. Crile G. Common sense in cancer. *Postgrad Med.* 1955;17:280-285.
22. Wangenstein OH, Lewis FJ, Arhelger SW. The extended or super-radical mastectomy for carcinoma of the breast. *Am Coll Surg Bull.* August 1956;79(8):1051-1063.
23. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. *N Engl J Med.* 1985;312(11):665-673.
24. NCI issues information on falsified data in NSABP trials. *J Natl Cancer Inst.* 1994;86(7):487-489.
25. Fraud in breast cancer trials. *N Engl J Med.* 1994;330(20):1458-1462. Correspondence.
26. Fisher B, Anderson S, Redmond C, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. *N Engl J Med.* 1995;333(22):1456-1461.
27. Fisher B. Dilemmas in breast disease. *Breast J.* 1995;1(6):380-385.
28. Silen W. Veritas, dogma, and numbers. *Arch Surg.* 1993;128:12-14.
29. Park WW, Lees JC. The absolute curability of cancer of the breast. *Surg Gynecol Obstet.* 1951;93(2):129-152.
30. Bloom H, Richardson W, Harries E. Natural history of untreated breast cancer (1805-1933). *Br Med J.* 1962;2:213.
31. Henderson C, Canellos G. Medical progress: cancer of the breast. *N Engl J Med.* 1980;302(1):19.
32. Bloodgood JC. Comedo carcinoma of the female breast. *Am J Cancer.* 1934;22:842.
33. Gliedman M, Deckers P, Margolese R, Mueller CB, Norton L, Silen W. Problems in the management of carcinoma of the breast. *Contemp Surg.* 1994;44:352.
34. Folkman J. Angiogenesis and breast cancer. *J Clin Oncol.* 1994;12(3):441-443.
35. Løve SM. Quoted by: Sharp N. The politics of breast cancer. *Nurs Manage.* 1991;22(9):24-28.
36. Tabar L, Fagerberg C, Day N, et al. Breast cancer treatment and natural history: new insights from results of screening. *Lancet.* 1992;339:412-414.
37. Kattlove H, Liberati A, Keeler E, et al. Benefits and costs of screening and treatment for early breast cancer. *JAMA.* 1995;273(2):142-148.
38. Plotkin D. Good news and bad news about breast cancer. *The Atlantic Monthly.* June 1996.
39. Hellman S, Harris J. The appropriate breast cancer paradigm. *Cancer Res.* 1987;47:341.
40. Fisher B, Anderson S, Fisher E, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. *Lancet.* 1991;338(8763):327.
41. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. *N Engl J Med.* 1995;333(22):1444-1455.
42. Haffty B, Fischer D, Rose M, Beinfeld MS, McKhann C. Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data. *J Clin Oncol.* 1991;9(6):997-1003.
43. Schapira D, Urban N. Breast cancer surveillance. *JAMA.* 1991;265(3):380-382.
44. Del Turco MR, Palli D, Cariddi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer. *JAMA.* 1994;271(20):1593-1597.
45. Loprinzi C. It is now the age to define the appropriate follow-up of primary breast cancer patients. *J Clin Oncol.* 1994;12(5):881-883. Editorial.
46. Schapira D. Breast cancer surveillance: a cost-effective strategy. *Breast Cancer Res Treat.* 1994;271(20):1592.
47. Hellman S, Weichselbaum R. Radiation oncology and the new biology. *Cancer J.* 1995;1(3):174-179.
48. Deisseroth A, DeVita V. The cell cycle. *Cancer J.* 1995;1(1):15-21.
49. Powers CA. The technique of operations for cancers of the breast. *JAMA.* 1895;24:299-302.
50. Clifton L. *Quilting Poems 1987-1990*. Brockport, NY: BoA Editions Ltd; 1991:29.
51. Holman HR. The 'excellence' deception in medicine. *Hosp Pract.* April 1976:11.
52. Jung CG. *The Structure and Dynamics of the Psyche*. New York, NY: Pantheon; 1960.
53. Peters V. Symposium on breast cancer. *Surg Clin North Am.* 1984;64(6):1153.
54. Selzer R. The exact location of the soul. *Mortal Lessons*. New York, NY: Simon & Shuster; 1974:15-23.
55. Wood C. Is hope a treatment for cancer? *Advances.* 1996;12(3):67-71.